Vol 72, No 3 (2021)
Clinical vignette
Published online: 2021-03-22
Giant silent corticotrope pituitary adenoma in a patient with complicated clinical course
Abstract
Not required for Clinical Vignette.
Keywords: acromegalyCushing´s diseasesomatostatin receptor subtypeimmunohistochemistrysomatostatin analogues
References
- Dai C, Liu X, Ma W, et al. The Treatment of Refractory Pituitary Adenomas. Front Endocrinol (Lausanne). 2019; 10: 334.
- de Bruin C, Feelders RA, Lamberts SWJ, et al. Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome. Rev Endocr Metab Disord. 2009; 10(2): 91–102.
- de Herder WW, Reijs AEM, Feelders RA, et al. Diagnostic imaging of dopamine receptors in pituitary adenomas. Eur J Endocrinol. 2007; 156 Suppl 1: S53–S56.
- Liu H, Zakiniaeiz Y, Cosgrove KP, et al. Toward whole-brain dopamine movies: a critical review of PET imaging of dopamine transmission in the striatum and cortex. Brain Imaging Behav. 2019; 13(2): 314–322.
- de Bruin C, Pereira AM, Feelders RA, et al. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab. 2009; 94(4): 1118–1124.
- Gabalec F, Beranek M, Netuka D, et al. Dopamine 2 receptor expression in various pathological types of clinically non-functioning pituitary adenomas. Pituitary. 2012; 15(2): 222–226.
